Saturday, Sep 19, 2020 | Last Update : 09:36 PM IST

179th Day Of Lockdown

Maharashtra114584081235431351 Andhra Pradesh6095585198915244 Tamil Nadu5309084757178685 Karnataka5029823940257808 Uttar Pradesh3362942632884771 Delhi2347011981034877 West Bengal2155801870614183 Odisha167161133466722 Telangana1670461353571016 Bihar164224149722855 Assam150349121610528 Kerala12221687341490 Gujarat119088999083271 Rajasthan109088906851293 Haryana103773816901069 Madhya Pradesh97906743981877 Punjab90032658182646 Chhatisgarh7777541111628 Jharkhand6710052807590 Jammu and Kashmir5971138521951 Uttarakhand3713924810460 Goa2678320844327 Puducherry2142816253431 Tripura2069612956222 Himachal Pradesh11190691997 Chandigarh92566062106 Manipur8430653951 Arunachal Pradesh6851496713 Nagaland5306407910 Meghalaya4356234232 Sikkim2119178923 Mizoram15069490
  Business   Companies  05 Aug 2020  Lupin launches Covihalt at Rs 49 per tablet for COVID treatment

Lupin launches Covihalt at Rs 49 per tablet for COVID treatment

PTI
Published : Aug 5, 2020, 3:30 pm IST
Updated : Aug 5, 2020, 3:30 pm IST

Favipiravir has received authorisation from the Drug Controller General of India for emergency use, Lupin said

 Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet. (Representative Image)
  Lupin launches COVID-19 drug Favipiravir in India at Rs 49 per tablet. (Representative Image)

New Delhi: Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name 'Covihalt' for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.

Favipiravir has received authorisation from the Drug Controller General of India (DCGI) for emergency use, Lupin said in a regulatory filing.

 

Its Covihalt dosage strength has been developed keeping in mind convenience of administration, it stated, adding that the drug is available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet.

Lupin President - India Region Formulations (IRF) Rajeev Sibal said the company believes that it can leverage its expertise in managing widespread community diseases like tuberculosis to proactively reach patients across India and ensure access to Covihalt through its strong distribution network and field force.

On August 4, Sun Pharmaceutical Industries had launched Favipiravir under the brand name ''FluGuard'' for the treatment of mild to moderate cases of COVID-19, at Rs 35 per tablet in India.

 

Shares of Lupin were trading 0.32 per cent higher at Rs 943.70 apiece on BSE.

Tags: lupin, lupin favipiravir, favipiravir by lupin, lupin launches favipiravir, lupin favipiravir price
Location: India, Delhi, New Delhi